Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015 Mar 14;385(9972):956-65. Epub 2014 Nov 7.

PubMed ID: 25468160
Public Release Type: Journal
Publication Year: 2015
Affiliation: The National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
DOI: https://doi.org/10.1016/S0140-6736(14)61933-4
Authors: Clark JM, Whitington P, Xanthakos S, Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, NASH Clinical Research Network, Dasarathy S, Dasarathy J, Hawkins C, McCullough AJ, Dasarathy S, McCullough AJ, Pagadala M, Pai R, Sargent R, Abdelmalek MF, Bashir M, Buie S, Diehl AM, Guy C, Kigongo C, Pan YP, Piercy D, Chalasani N, Cummings OW, Gawrieh S, Ghabril M, Marri S, Ragozzino L, Sandrasegaran K, Vuppalanchi R, King D, Osmack P, Siegner J, Stewart S, Neuschwander-Tetri BA, Torretta S, Ang B, Behling C, Bhatt A, Lavine J, Loomba R, Middleton M, Patton H, Sirlin C, Aouizerat B, Bass NM, Brandman D, Ferrell LD, Gill R, Hameed B, Ramos C, Terrault N, Ungermann A, Atla P, Croft B, Garcia R, Garcia S, Sheikh M, Singh M, Boyett S, Carucci L, Contos MJ, Kraft K, Luketic VA, Puri P, Sanyal AJ, Schlosser J, Siddiqui MS, Wolford B, Ackermann S, Cooney S, Coy D, Gelinas K, Kowdley KV, Lee M, Pierce T, Mooney J, Nelson JE, Shaw C, Siddique A, Wang C, Brunt EM, Fowler K, Kleiner DE, Brown SR, Doo EC, Hoofnagle JH, Robuck PR, Sherker A, Torrance RJ, Belt P, Donithan M, Hallinan E, Isaacson M, May KP, Miriel L, Sternberg A, Tonascia J, Ünalp-Arida A, Van Natta M, Vaughn I, Wilson L, Yates K, Lavine J, Sanyal A, Barlow S, Chalasani N, Doo E, Diehl AM, Kowdley K, Loomba R, McCullough A, Molleston J, Murray K, Rosenthal P, Sirlin C, Schwimmer J, Terrault N, Neuschwander-Tetri B, Tonascia J
Studies: Nonalcoholic Steatohepatitis Clinical Research Network , The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment

Abstract

The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis.

Home chevron_right Publications chevron_right Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Abstract